Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination

We assessed human papillomavirus (HPV) prevalence among HPV-16/18-vaccinated and unvaccinated Finnish male adolescents participating in chlamydia screening 4 years after vaccination with AS04-adjuvanted HPV-16/18 vaccine in 2007-2009. Previously vaccinated (n = 395) or unvaccinated (n = 149) male adolescents were enrolled in 12 municipalities. First-void urine samples were tested for HPV types 6, 11, 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, 59, 66, and 68, and prevalence rates for HPV-16/18, and HPV-11/16/18/31/33/45 were reduced profoundly (0% vs 2.1% [P = .02] and 0.8% vs 5.3 [P = .002], respectively). Overall HPV DNA prevalence was also significantly reduced among HPV-16/18-vaccinated (4.1%) compared with unvaccinated subjects (10.1%) (P = .01). In this post hoc study, a highly significant reduction in HPV prevalence 4 years after vaccination suggests that the bivalent HPV-16/18 vaccine has protective efficacy in men.

[1]  Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. , 2017, Vaccine.

[2]  M. Lehtinen,et al.  Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. , 2015, Vaccine.

[3]  H. Cubie,et al.  Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types , 2014, British Journal of Cancer.

[4]  M. Lehtinen,et al.  Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation , 2013, The Journal of infectious diseases.

[5]  C. Wheeler,et al.  Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[6]  A. Moscicki,et al.  Human Papillomavirus in Men: An Update , 2011, Journal of lower genital tract disease.

[7]  H. Jessen,et al.  Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. , 2011, The New England journal of medicine.

[8]  H. Jessen,et al.  External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. , 2011, The Journal of infectious diseases.

[9]  J. Carlson,et al.  Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human Papillomavirus , 2009, Journal of Clinical Microbiology.

[10]  A. Giuliano,et al.  Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. , 2009, The Journal of infectious diseases.

[11]  M. Lehtinen,et al.  Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. , 2009, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[12]  Ji‐Hyun Lee,et al.  Correlates of Human Papillomavirus Viral Load with Infection Site in Asymptomatic Men , 2008, Cancer Epidemiology Biomarkers & Prevention.

[13]  Ji‐Hyun Lee,et al.  The Human Papillomavirus Infection in Men Study: Human Papillomavirus Prevalence and Type Distribution among Men Residing in Brazil, Mexico, and the United States , 2008, Cancer Epidemiology Biomarkers & Prevention.

[14]  M. Lehtinen,et al.  Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy , 2006, International journal of STD & AIDS.

[15]  M. Abba,et al.  Human papillomavirus DNA detection and typing in male urine samples from a high-risk population from Argentina. , 2005, Journal of virological methods.